Company: NCNA
Filing Date: 2025-06-18
Form Type: F-3/A
Source: 0001193125-25-142565
Chunk: 6

Company: NuCana plc
Filing Date: 2025-06-18
Form: F-3/A
Chunk 6
---
 prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many
solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key
limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that
disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is
evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a new chemical
entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in a Phase 1b/2 modular study
(NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with
lung cancer.

Additional Information

For additional information related to our business and operations, please refer to the reports incorporated herein by reference, including the
Annual Report on Form 20-F of NuCana plc for the year ended December 31, 2024 and the Report on Form 6-K furnished on June 2, 2025, as described under the
caption “Incorporation of Documents by Reference” on page 54 of this prospectus.

Our Corporate Information

NuCana was incorporated under the laws of England and Wales in 1997 under the name Biomed (UK) Limited, and commenced operations in 2008. On
April 28, 2008, we changed our name to NuCana BioMed Limited. On August 29, 2017, we re-registered as a public limited company and changed our name to NuCana plc. ADSs representing our ordinary
shares were admitted to trading on The Nasdaq Global Select Market on September 28,